CS
NBSE

Credit Suisse’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Credit Suisse’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-65
Closed -$84K – 4380
2016
Q1 		$84K Buy
+65
New +$92.6K ﹤0.01% 3848
2015
Q3 		– Sell
-76
Closed -$77K – 4532
2015
Q2 		$77K Buy
76
+9
+13% +$9.71K ﹤0.01% 4416
2015
Q1 		$68K Buy
+67
New +$221K ﹤0.01% 4262
2014
Q2 		– Sell
-122
Closed -$663K – 4837
2014
Q1 		$663K Buy
+122
New +$643K ﹤0.01% 3499

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Credit Suisse's NBSE Position: Q2 2016 in Review

Credit Suisse sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2016, closing a stake of 65 shares — an estimated $84K sold.

Credit Suisse first reported a position in NBSE in Q1 2014 and held it in 4 quarters. The position peaked at $663K in Q1 2014. 51 funds tracked by Wall St. Rank hold NBSE as of Q2 2016.

  • Credit Suisse reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • Credit Suisse sold 65 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $84K.
  • Credit Suisse first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 4 quarters.
  • Credit Suisse's NeuBase Therapeutics, Inc. Common Stock position peaked at $663K in Q1 2014.
  • 51 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Credit Suisse's 13F filing for Q2 2016, filed 11 Aug 2016.